Hongjiang Pu

Dr. Hongjiang Pu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
BZBing Zou
Bing Zou
JJJiezhi Jiang
Jiezhi Jiang
MLMengmei Liu
Mengmei Liu
YCYaxue Chen
Yaxue Chen
YJYan Jin
Yan Jin
HPHongjiang Pu
Hongjiang Pu
Objective: Epidemiological data concerning Burkitt Lymphoma (BL) in children aged 0–14 years remain limited. This study examines the trends in incidence, mortality, and disability-adjusted life years (DALYs), as well as the estimated annual percentage change (EAPC) associated with childhood Burkitt Lymphoma within this demographic from 1990 to 2021.Methods: The 2021 Global Burden of Disease, Injuries, and Risk Factors Study (GBD) analytical tools were utilized to evaluate the incidence, mortality, and disability-adjusted life years (DALYs) associated with childhood Burkitt Lymphoma in individuals aged 0–14 years. This analysis incorporated variables such as age, sex, region, and sociodemographic index (SDI), utilizing data from 204 countries or regions. A comprehensive examination of health disparities was undertaken to investigate variations in mortality and DALYs among different population groups. Additionally, the Bayesian age-period-cohort (BAPC) model was employed to forecast incidence, mortality, and DALYs through the year 2035.Results: In 2021, a total of 4,083 cases of childhood Burkitt Lymphoma were documented globally. This represents an increase from 2,800 cases reported in 1990, with a 95% uncertainty interval (UI) ranging from 1,609.001 to 3,989.282, to 4,083 cases in 2021 (95% UI, 2,619.594 to 5,376.872), indicating a 31.45% rise over the period. During this 30-year span, the global incidence rate escalated from 0.172 per 100,000 individuals in 1990 (95% UI, 0.099 to 0.245) to 0.216 per 100,000 individuals in 2021 (95% UI, 0.138 to 0.285). Concurrently, the mortality rate associated with childhood Burkitt Lymphoma increased from 0.152 per 100,000 individuals in 1990 (95% UI, 0.079 to 0.224) to 0.163 per 100,000 individuals in 2021 (95% UI, 0.100 to 0.216). The highest incidence in 2021 was recorded in Sub-Saharan East Africa, while Sub-Saharan Southern Africa experienced the most pronounced increase in incidence, with an annual percent change (APC) of 3.226% (95% confidence interval [CI]: 2.092–4.373%). The age group most affected was children aged 5–9 years, who constituted 33.3% of the cases.Conclusion: Between 1990 and 2021, there was a notable rise in the incidence of childhood Burkitt Lymphoma, with a pronounced increase observed in Sub-Saharan Africa. The age group of 5–9 years exhibited the highest incidence and mortality rates, underscoring the critical need for early diagnosis and intervention. Although regions with high Socio-Demographic Index (SDI) have demonstrated advancements in reducing mortality rates, areas with low SDI necessitate improved medical resources and the implementation of standardized treatment protocols. The escalating incidence in specific regions underscores the urgent need for comprehensive research into the disease’s etiology and the development of enhanced prevention strategies.

1 March 2021 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
HPHongjiang Pu
Hongjiang Pu
PXPeiyi Xie
Peiyi Xie
YCYaxue Chen
Yaxue Chen
YZYanrong Zhao
Yanrong Zhao
XYXi Ye
Xi Ye
ZLzhenhui Li
zhenhui Li
Purpose: Based on a multi-centered and a large sample size, this study aims to analyze the relationship between preoperative and postoperative serum CEA and recurrence of rectal cancer without preoperative therapy. Methods: This retrospective cohort study enrolled stage I to III rectal cancer patients without preoperative therapy (N = 1,022) who received radical resection of rectal cancer from 2 hospitals in China. Based on the preoperative and postoperative serum carcinoembryonic antigen, the patients were subdivided into 3 groups ie, normal preoperative CEA (≤ 5.0 ng/mL, N = 627), elevated preoperative (> 5.0 ng/mL) but normalized postoperative CEA (normalized postoperative CEA, N = 255), as well as elevated preoperative and postoperative CEA (elevated postoperative CEA, N = 67). The generalized additive model was used to assess the relationship between carcinoembryonic antigen and the risk of recurrence. Further, the Cox regression model was used to evaluate the relationship between carcinoembryonic antigen and 3-year recurrence-free survival (RFS) after adjusting for potential confounders. Results: The 3-year RFS of patients with elevated postoperative CEA was 45.8% (95% CI, 35.2% − 59.5%), which was significantly lower compared to the other two groups of patients (normalized postoperative CEA: 75.9%, 95% CI, 70.8%-81.4%; and normal preoperative CEA: 84.9%, 95% CI, 82.2%-87.8%) (P < 0.001). Based on multivariable Cox model analysis, the elevated postoperative CEA was a prognostic factor for 3 years RFS (hazard ratio [HR], 3.08; 95% CI, 2.05– 4.66; P< 0.001). At the same time, normalized postoperative CEA was insignificantly correlated with 3-year RFS (HR, 1.38; 95% CI, 1.00– 1.92; P = 0.05) and was not an independent risk factor. Conclusion: We found that preoperative and postoperative serum CEA of rectal cancer patients were related to the 3-year recurrence-free survival rate. Moreover, the risk of recurrence in the normalized postoperative CEA group of patients was insignificantly different from that of the normalized preoperative CEA patients. Therefore, it is necessary to combine preoperative and postoperative CEA to predict the prognosis of patients with rectal cancer, rather than using it alone.

1 March 2023 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
JHJing Huang
Jing Huang
HPHongjiang Pu
Hongjiang Pu
JHJintao He
Jintao He
XTXiaohu Tang Tang
Xiaohu Tang Tang
Background: Most cancer-related deaths around the globe are caused by lung cancer. The present treatments for metastatic non-small cell lung cancer (mNSCLC) are cytotoxic chemotherapy (CCT), targeted therapy (TT) and immunotherapy, but the benefit of the same regime varies greatly. Hence, it is important to identify biomarkers to predict the efficacy of modalities. Previous literature suggested certain parameters might be predictive factors. Nevertheless, the utility of these parameters is limited due to the types of solid tumors. Purpose: The study aimed to examine whether the lung immune prognostic index (LIPI) was related to outcomes of CCT, immune checkpoint inhibitors (ICIs) and TT for mNSCLC patients. Materials and Methods: A retrospective cohort study between September 2012 and May 2020 was conducted on 350 Chinese mNSCLC patients, including 147 patients receiving ICIs, 103 TT, and 100 CCT. The data were examined to analyze the prognostic value of LIPI among various treatments. Main Outcomes and Measures: The associations between PFS and good, intermediate, or poor prognostic LIPI scores in ICIs, TT, and CCT were determined, respectively. Results: In univariable analyses, there was a relevance between a good LIPI score and better PFS among patients receiving ICIs (HR, 0.81; 95% CI, 0.44– 1.51), TT (HR, 0.35; 95% CI, 0.16– 1.74), and CCT (HR, 0.39; 95% CI, 0.19– 0.80). In multivariable analyses, the intermediate LIPI score was linked to better PFS only in patients receiving TT (HR, 0.31; 95% CI, 0.17– 0.92) rather than ICIs (HR, 1.12; 95% CI, 0.66– 2.45) or CCT (HR, 1.24; 95% CI, 0.49– 4.55). Conclusion: Baseline LIPI value is an important prognostic biomarker for mNSCLC patients treated with TT. Shorter PFS with TT was associated with poor baseline LIPI. Poor LIPI score may be considered as a promising indicator showing which patients are unlikely to respond well to TT. The prognostic value of LIPI can be more clearly determined through prospective clinical study.

28 January 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XGXi Guo
Xi Guo
TXTingting Xu
Tingting Xu
YLYu Luo
Yu Luo
SLSiyuan Liu
Siyuan Liu
XTXiaoqing Tang
Xiaoqing Tang
HPHongjiang Pu
Hongjiang Pu
Lung cancer remains the leading cause of cancer-related incidence and mortality worldwide. Its tendency for postoperative distant metastasis significantly compromises long-term prognosis and survival. Accurately predicting the metastatic potential in a timely manner is crucial for formulating optimal treatment strategies. This study aimed to comprehensively compare the predictive performance of nine machine learning (ML) models and to enhance interpretability through SHAP (Shapley Additive Explanations), with the goal of developing a practical and transparent risk stratification tool for postoperative lung cancer management. Clinical data from 3,120 patients with stage I–III lung cancer who underwent radical surgery were retrospectively collected and randomly divided into training and testing cohorts. A total of 52 clinical, pathological, imaging, and laboratory variables were analyzed. Nine ML models—including eXtreme Gradient Boosting (XGBoost), Random Forest (RF), Light Gradient Boosting Machine (LightGBM), Adaptive Boosting (AdaBoost), Decision Tree (DT), Gradient Boosting Decision Tree (GBDT), Gaussian Naive Bayes (GNB), Complement Naive Bayes (CNB), and Multilayer Perceptron classifier (MLP)—were developed and evaluated. Model performance was assessed using accuracy, precision, recall, F1 score, ROC–AUC, PR–AUC, calibration, and decision curve analysis (DCA). All models were evaluated using nested cross-validation (outer stratified 70/30 splits repeated 10 times; inner fivefold tuning), with decision thresholds prespecified in the inner loop and applied unchanged to held-out tests. Given the approximately 4:1 class imbalance, cost-sensitive learning was primarily adopted, and PR-AUC was reported in addition to ROC-AUC. Among the nine models, GBDT demonstrated the highest predictive performance, achieving an AUC of 0.810 (95% CI: 0.748–0.872), accuracy of 0.766, sensitivity of 0.698, and specificity of 0.786 in the test set. SHAP analysis revealed that adjuvant chemotherapy, adjuvant radiotherapy, pathological N stage, age, body mass index (BMI), and preoperative neutrophil count (Pre-ANC) were the most influential predictors of distant metastasis. The combination of model performance and interpretability supported the model’s potential for integration into clinical workflows to assist in real-time decision-making. In this work, we carried out a systematic comparison of nine machine learning algorithms in a large postoperative cohort under a coherent and interpretable framework. By jointly considering discrimination, calibration, clinical benefit (via decision curve analysis), and SHAP-based explanations, we constructed a practical prognostic tool to guide personalized treatment strategies and follow-up care. This methodology offers a data-driven basis for precision management. Ultimately, our findings provide an internally validated reference framework that warrants external and multicenter validation prior to clinical deployment.

1 August 2023 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
LLLizhu Liu
Lizhu Liu
XPXiaolin Pang
Xiaolin Pang
KZKe Zhao
Ke Zhao
YCYaxue Chen
Yaxue Chen
YLYanli Li
Yanli Li
HPHongjiang Pu
Hongjiang Pu
Background: It is common for elderly patients to be underrepresented in clinical trials for cancer, which can result in a lack of efficacy data and unclear criteria to guide treatment decisions for clinical doctors. Therefore, one of the common challenges in oncology treatment is determining the extent to which patients aged 75 and older have benefited from postoperative chemotherapy. Purpose: The study aimed to explore the effect of adjuvant chemotherapy (AC) on 3-year recurrence-free survival (RFS) after curative resection in patients aged 75 years and older with stage II–III colorectal cancer (CRC). Methods: The retrospective cohort analysis was performed on patients with stage II–III CRC who received curative resection at three cancer centers in China between 2008 and 2017. Kaplan-Meier curves and Multivariable Cox regression models were used to analyze the impact of AC on RFS in patients. Finally, propensity-score matching was used to reduce selection bias and confounding factors in patients aged 75 years and older with stage II–III CRC. Results: A total of 2885 patients were included (1729 (59.9%) male; 1312 (61.5%) received AC). The pre-matching cohort was comprised of 151 patients aged 75 years and older (median age (IQR)77.00 (76.00, 79.00); 97 (64.2%) male, 51 (72.9%) received AC). Age (P=0.001), postoperative carcinoembryonic antigen (CEA)(P=0.02) level were associated with prognosis. But AC was not associated with 3-year RFS (HR, 1.27; 95% CI, 0.80– 2.0; log-rank P=0.37). After a predisposition 1: 1 match (with or without AC, n = 42), AC remains uncorrelated with 3-year RFS (HR, 1.39; 95% CI, 0.52– 3.70; log-rank P=0.66). Conclusion: Patients over the age of 75 with stage II–III CRC who receive AC or do not face the same risk of postoperative recurrence. As a result, patients with stage II–III postoperative adjuvant chemotherapy can make an informed decision regarding whether they want to undergo chemotherapy based on their age and reduce the unnecessary side effects of chemotherapy.

8 August 2025 in BMC Cancer
Verified
Journal Article
Open access
MBMaoshu Bai
Maoshu Bai
LLLizhu Liu
Lizhu Liu
MLMengmei Liu
Mengmei Liu
XLXin Liu
Xin Liu
TXTingting Xu
Tingting Xu
ZLzhenhui Li
zhenhui Li
Preoperative MRI staging offers a noninvasive approach to assess local tumor invasion and distant metastasis. Attention has been paid to investigating the impact of preoperative abdominal MRI staging on the prognosis of patients with stage II-III colon cancer. Patients who underwent radical resection for stage II-III colon cancer at Yunnan Cancer Hospital between 2008 and 2017 were retrospectively analyzed and divided into preoperative MRI and non-MRI groups. Propensity score matching (PSM) was applied to balance patient characteristics. Overall survival (OS) and Disease-free survival (DFS) were compared using the Kaplan–Meier method and log-rank test. Additionally, Cox regression was used to evaluate the correlation between preoperative MRI and prognosis, and subgroup analyses further compared the two groups. For multivariable analysis, two models were constructed and compared. Among 1086 patients included, 29.28% underwent preoperative abdominal MRI. Patients who received preoperative MRI demonstrated better OS (log-rank p = 0.002), particularly those with stage III colon cancer (p < 0.05). After PSM, the MRI group exhibited significantly better 5-year OS (90.0% vs. 82.0%, P = 0.019) and a lower risk of death (HR, 1.66; 95% CI, 1.07–2.56; P = 0.024). Subgroup analysis revealed that the OS of preoperative MRI was significant in stage III patients. However, no significant difference was observed in DFS between the two groups. Furthermore, compared to the MRI group, the non-MRI group showed a statistically significant increased risk in model 1 (OR = 1.63, 95% CI: 1.08–2.44, P = 0.020) and model 2 (OR = 1.79, 95% CI: 1.17—2.73, P = 0.007) in terms of OS. Preoperative abdominal MRI significantly enhances OS in patients with stage II-III colon cancer, especially in those with stage III disease. However, the specific role of MRI in treatment planning, as well as the potential impact of different treatment approaches on outcomes, warrants further investigation into the treatment decision-making processes. The online version contains supplementary material available at 10.1186/s12885-025-14652-5.